Radiodermatitis (radiation dermatitis, radiation-related skin reactions, or radiation damage) is a serious side effect of ionizing radiation  during cancer therapy and nuclear attacks and disasters such as  Fukushima in 2011. Specifically, 95% of cancer patients receiving radiation therapy  develop some form of radiation dermatitis, including erythema. , dry scale and moist scale. These  skin reactions to radiation lead to countless complications, such as treatment delays, reduced aesthetic appeal, and reduced quality of life. Recent technological advances and new treatment regimens have only partially succeeded in alleviating these harmful side effects. The most common cause of radiation dermatitis is radiation therapy, which is used to treat cancer and other disorders. Disasters and nuclear assaults may also contribute to the condition. Retail pharmacies and online pharmacies are included in the distribution route.

Market Dynamics

Radiation dermatitis, also known as X-ray rash, radiation dermatitis, radiation skin reactions or radiation damage, is a side effect of external ionizing radiation. Radiation therapy, used to treat cancer or other diseases, is a leading cause of radiation dermatitis. Nuclear attacks and disasters can also cause the condition. For instance, on May 14, 2020, an article published by National Center for Biotechnology Information (NCBI) explained none of the recommended products for patients are based on evidence-based practice, and the effectiveness of these products in preventing or treating radiation dermatitis is not reliable. It has previously been suggested that moist skin care with urea cream is effective in reducing the severity of acute skin reactions. In addition, recent reports have recommended the use of steroids, calendula, Hypericum perforatum, and neem oil for the treatment of acute radiodermatitis.

Key features of the study:                                                                                                               

• This report provides an in-depth analysis of the global radiodermatitis market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global radiodermatitis market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Acelity, Inc. (3M), BMG Pharma S.r.l., ConvaTec Group PLC, DermaSciences Inc. (Integra LifeSciences Holdings Corporation), Intermed Pharmaceuticals, Mölnlycke Health Care, Smith & Nephew Plc, Stratpharma AG, Kannalife, Inc., McKesson Corporation.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global radiodermatitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global radiodermatitis market.

Detailed Segmentation:

• Global Radiodermatitis Market, By Product Type:
  • Topical Agents
    • Corticosteroids
    • Hydrophilic Creams
    • Others
  • Oral Medication
    • Corticosteroids
    • Other
      • Analgesic & Anti-Inflammatory
  • Dressing
    • Hydrogel, Hydrocolloid
    • No Sting Barrier Film
    • Honey Impregnated Dressing
    • Silicone coated Dressing
    • Others
• Global Radiodermatitis Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Radiodermatitis Market, By Region:
  • North America
    
    • U.S.
    • Canada
  • Latin America
    
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Acelity, Inc. (3M)
  • BMG Pharma S.r.l.
  • ConvaTec Group PLC
  • DermaSciences Inc. (Integra LifeSciences Holdings Corporation)
  • Intermed Pharmaceuticals
  • Mölnlycke Health Care
  • Smith & Nephew Plc.
  • Stratpharma AG
  • Kannalife, Inc.
  • McKesson Corporation